HBeAg and hepatitis B Virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B

Hepatology

Volumn 47, Issue 2, 2008, Pages 428-434

  Fried, Michael W ^a   Piratvisuth, Teerha ^b   Lau, George K K ^c   Marcellin, Patrick ^d   Chow, Wan Cheng ^e   Cooksley, Graham ^f   Luo, Kang Xian ^g   Paik, Seung Woon ^h   Liaw, Yun Fan ⁱ   Button, Peter ^j   Popescu, Matei ^k  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d University of Paris   (France)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g FIRST MILITARY MEDICAL UNIVERSITY   (China)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j Roche   (Australia)

^k F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG MONITORING; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 39549114267     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22065     Document Type: Article

References (45)

1. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. HEPATOLOGY 2003;37:1309-1319.
2. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002;17:409-414.
3. Zhou XX, Littler E. Nucleoside analogs as anti-HBV agents. Curr Top Med Chem 2006;6:851-865.
4. Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. HEPATOLOGY 1986;6:167-172.
5. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
6. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Vital Hepatitis (EUROHEP). HEPATOLOGY 1997;26:1338-1342.
7. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-1325.
8. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. HEPATOLOGY 1989;10:761-763.
9. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
10. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992;102:2091-2097.
11. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650.
12. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
13. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1-46.
14. Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep 2004;6:17-21.
15. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996;91:2323-2328.
16. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
17. Guan R. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005;60:28-33.
18. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000;7:382-386.
19. van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005;12:364-372.
20. Zeuzem S, Lai CL, Gane E, Liaw YF, Thongsawat S, Wang Y, et al. Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients. In: 41st Annual Meeting of the European Association for the Study of the Liver. Vienna, Austria: April 26-30, 2006.
21. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. HEPATOLOGY 1993;18:1306-1312.
22. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695.
23. Kessler HH, Pierer K, Dragon E, Lackner H, Santner B, Stunzner D, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998;9:37-43.
24. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform 2005;38:404-415.
25. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
26. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-686.
27. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. HEPATOLOGY 2004;39:857-861.
28. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962.
29. Laperche S, Thibault V, Bouchardeau F, Alain S, Castelain S, Gassin M, et al. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol 2006;44:3600-3607.
30. Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, et al. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000;85:11-21.
31. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122:1554-1568.
32. Magnius LO, Espmark JA. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol 1972;109:1017-1021.
33. Shikata T, Karasawa T, Abe K, Uzawa T, Suzuki H, Oda T, et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977;136:571-576.
34. Luo KX, Zhou R, Liang ZS, Jiang S. Correlation between the prevalence of serum HBV DNA and immunoserologic HBV markers in the subjects with or without hepatitis. Immunol Invest 1992;21275-21281.
35. Yuen MF, Fung SK, Tanaka Y, Kato T, Mizokami M, Yuen JC, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004;42:5036-5040.
36. Gish RG, Locarnini SA. Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006;4:666-676.
37. Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980;79:195-199.
38. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748.
39. Miyakawa Y, Mayumi M. Hepatitis B e antigen and antibody (HBeAg/anti-HBe). In: Gerety RJ, ed. Hepatitis B. Orlando, FL: Academic Press; 1985:47-76.
40. Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
41. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
42. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388-390.
43. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
44. Dienstag JL, SchiffER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
45. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-1282.